Akasaka Takashi, Lossos Izidore S, Levy Ronald
Division of Oncology, Department of Medicine, Stanford University Medical Center, CA, USA.
Blood. 2003 Aug 15;102(4):1443-8. doi: 10.1182/blood-2002-08-2482. Epub 2003 May 8.
Follicular lymphoma (FL) is characterized by a relatively indolent clinical course, but the disease often transforms into a more aggressive large cell lymphoma with a rapidly progressive clinical course. In the present study, we analyzed 41 cases of FL known to have subsequently transformed to aggressive lymphoma and an additional 64 FL samples from patients not subsequently transformed. We studied BCL6 gene rearrangement by the methodology of long-distance inverse polymerase chain reaction (LDI-PCR). Of the 41 cases known to transform, 16 (39.0%) harbored BCL6 translocation or deletion at the time of FL diagnosis. Among 64 cases not known to transform, BCL6 translocation was detected in 9 (14.1%). The prevalence of BCL6 translocation in the group known to transform was significantly higher (P =.0048). Among the transformation cases, the partners of the BCL6 translocation were identified in 13 cases and included IGH, CIITA, U50HG, MBNL, GRHPR, LRMP, EIF4A2, RhoH/TTF, and LOC92656 (similar to NAPA), whereas in the control group the BCL6 partners were IGH, CIITA, SIAT1, and MBNL. In 13 cases paired specimens before and after transformation were available. Among these paired specimens, a loss (3 cases) or a gain (1 case) of BCL6 translocation was observed after the transformation. Analysis of clonality showed that all of these cases represented the evolution of a subclone of the original tumor population. Our study demonstrated that BCL6 translocation is not necessary for transformation but that BCL6 translocation in FL may constitute a subgroup with a higher risk to transform into aggressive lymphoma.
滤泡性淋巴瘤(FL)的临床病程相对惰性,但该疾病常转化为临床病程进展迅速的侵袭性更强的大细胞淋巴瘤。在本研究中,我们分析了41例已知随后转化为侵袭性淋巴瘤的FL病例以及另外64例未发生后续转化的患者的FL样本。我们采用长距离反向聚合酶链反应(LDI-PCR)方法研究BCL6基因重排。在已知发生转化的41例病例中,16例(39.0%)在FL诊断时存在BCL6易位或缺失。在64例未知发生转化的病例中,9例(14.1%)检测到BCL6易位。已知发生转化的组中BCL6易位的发生率显著更高(P = 0.0048)。在转化病例中,13例确定了BCL6易位的伙伴基因,包括IGH、CIITA、U50HG、MBNL、GRHPR、LRMP、EIF4A2、RhoH/TTF和LOC92656(类似于NAPA),而在对照组中,BCL6的伙伴基因是IGH、CIITA、SIAT1和MBNL。在13例病例中可获得转化前后的配对标本。在这些配对标本中,转化后观察到BCL6易位有丢失(3例)或增加(1例)。克隆性分析表明,所有这些病例均代表原始肿瘤群体亚克隆的演变。我们的研究表明,BCL6易位并非转化所必需,但FL中的BCL6易位可能构成一个转化为侵袭性淋巴瘤风险更高的亚组。